Sarah E. Fenton

1.2k total citations
27 papers, 388 citations indexed

About

Sarah E. Fenton is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Sarah E. Fenton has authored 27 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Sarah E. Fenton's work include Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (6 papers) and Prostate Cancer Treatment and Research (5 papers). Sarah E. Fenton is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Melanoma and MAPK Pathways (6 papers) and Prostate Cancer Treatment and Research (5 papers). Sarah E. Fenton collaborates with scholars based in United States, United Kingdom and Australia. Sarah E. Fenton's co-authors include Diana Saleiro, Leonidas C. Platanias, Mitchell F. Denning, Jeffrey A. Sosman, Sunandana Chandra, Sylvie M. Guichard, Paul D. Smith, Máiréad Kiely, Brendan P. Murphy and Sarah V. Holt and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Sarah E. Fenton

26 papers receiving 387 citations

Peers

Sarah E. Fenton
Toshifumi Hoki Japan
Tess Schmalbach United States
Yuko Takano Japan
André Jefremow Germany
Han-Kwang Yang South Korea
Byung Soo Kim South Korea
John Eklund United States
Namratha Sheshadri United States
Kathryn S. McKee United States
Siyu Tan China
Toshifumi Hoki Japan
Sarah E. Fenton
Citations per year, relative to Sarah E. Fenton Sarah E. Fenton (= 1×) peers Toshifumi Hoki

Countries citing papers authored by Sarah E. Fenton

Since Specialization
Citations

This map shows the geographic impact of Sarah E. Fenton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah E. Fenton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah E. Fenton more than expected).

Fields of papers citing papers by Sarah E. Fenton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah E. Fenton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah E. Fenton. The network helps show where Sarah E. Fenton may publish in the future.

Co-authorship network of co-authors of Sarah E. Fenton

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah E. Fenton. A scholar is included among the top collaborators of Sarah E. Fenton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah E. Fenton. Sarah E. Fenton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Stewart, Tyler F., Sarah E. Fenton, Shayan Nazari, et al.. (2024). Landscape analysis and oncologic outcomes in advanced urothelial carcinoma (UC) by NECTIN4 RNA expression.. Journal of Clinical Oncology. 42(16_suppl). 4585–4585. 1 indexed citations
2.
Fenton, Sarah E., Masha Kocherginsky, David James VanderWeele, & Maha Hussain. (2024). A randomized phase II study of ADT + abiraterone versus ADT + abiraterone + docetaxel in patients with low-volume metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology. 42(16_suppl). TPS5121–TPS5121.
3.
Fenton, Sarah E. & Maha Hussain. (2024). Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?. Expert Opinion on Investigational Drugs. 33(10). 993–999. 1 indexed citations
4.
Fenton, Sarah E. & David James VanderWeele. (2023). Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma. Frontiers in Oncology. 12. 1069356–1069356. 7 indexed citations
5.
Fenton, Sarah E., Μαρκέλλα Ζαννίκου, Mariafausta Fischietti, et al.. (2022). Targeting ULK1 Decreases IFNγ-Mediated Resistance to Immune Checkpoint Inhibitors. Molecular Cancer Research. 21(4). 332–344. 10 indexed citations
6.
Weiner, Adam B., Aisha L. Siebert, Sarah E. Fenton, et al.. (2022). First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. European Urology Oncology. 5(4). 377–387. 3 indexed citations
7.
Fenton, Sarah E., Michael C. Burns, & Aparna Kalyan. (2021). Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chinese Clinical Oncology. 10(1). 2–2. 12 indexed citations
8.
Fenton, Sarah E., Sheetal Kircher, Mary F. Mulcahy, et al.. (2021). A phase I study of nivolumab (NIVO) in combination with TheraSphere (Yttrium-90) in patients with advanced hepatocellular cancer.. Journal of Clinical Oncology. 39(15_suppl). e16183–e16183. 13 indexed citations
9.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2020). Abstract 3418: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The salivary gland tumor cohort. Cancer Research. 80(16_Supplement). 3418–3418. 5 indexed citations
10.
Fenton, Sarah E., et al.. (2020). Hyperacute Onset of Immune Checkpoint Inhibitor–Related Acute Interstitial Nephritis. Kidney International Reports. 5(11). 2084–2088. 4 indexed citations
11.
Chae, Young Kwang, Megan Othus, Sandip Pravin Patel, et al.. (2020). Abstract 3417: A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: The small bowel tumor cohort. Cancer Research. 80(16_Supplement). 3417–3417. 5 indexed citations
12.
Fenton, Sarah E., Jeffrey A. Sosman, & Sunandana Chandra. (2019). Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors. Cancer Drug Resistance. 2(3). 744–761. 15 indexed citations
13.
Kiely, Máiréad, et al.. (2018). Standardized Parenteral Nutrition for the Transition Phase in Preterm Infants: A Bag That Fits. Nutrients. 10(2). 170–170. 15 indexed citations
14.
Fenton, Sarah E., et al.. (2017). Transition Phase Nutrition Recommendations: A Missing Link in the Nutrition Management of Preterm Infants. Journal of Parenteral and Enteral Nutrition. 42(2). 343–351. 18 indexed citations
15.
Fenton, Sarah E., Jeffrey A. Sosman, & Sunandana Chandra. (2017). Emerging growth factor receptor antagonists for the treatment of advanced melanoma. Expert Opinion on Emerging Drugs. 22(2). 165–174. 1 indexed citations
16.
Fenton, Sarah E. & Mitchell F. Denning. (2014). FYNagling divergent adhesive functions for Fyn in keratinocytes. Experimental Dermatology. 24(2). 81–85. 3 indexed citations
17.
Fenton, Sarah E., et al.. (2014). Targeting Fyn in Ras‐transformed cells induces F‐actin to promote adherens junction‐mediated cell–cell adhesion. Molecular Carcinogenesis. 54(10). 1181–1193. 15 indexed citations
18.
Holt, Sarah V., Armelle Logié, Barry R. Davies, et al.. (2012). Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055). Cancer Research. 72(7). 1804–1813. 70 indexed citations
19.
Marshall, Gayle, Zoë Howard, Jonathan R. Dry, et al.. (2011). Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochemical Society Transactions. 39(2). 456–459. 28 indexed citations
20.
Yadav, Vipin, et al.. (2010). Loss of Protein Kinase C δ Gene Expression in Human Squamous Cell Carcinomas. American Journal Of Pathology. 176(3). 1091–1096. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshifumi Hoki Breakdown of academic impact, for papers by Tess Schmalbach Breakdown of academic impact, for papers by Yuko Takano Breakdown of academic impact, for papers by André Jefremow Breakdown of academic impact, for papers by Han-Kwang Yang Breakdown of academic impact, for papers by Byung Soo Kim Breakdown of academic impact, for papers by John Eklund Breakdown of academic impact, for papers by Namratha Sheshadri Breakdown of academic impact, for papers by Kathryn S. McKee Breakdown of academic impact, for papers by Siyu Tan
Rankless by CCL
2026